Substance Addiction and Cardiovascular Effects

Güngör, D. (2018). Sentetik uyuşturucular: Amfetamin örneği. Güvenlik Çalışmaları Dergi- si, 20(1), 105-112.

Ögel, K., Tamar, D.K.A., et al. (Eds.). (1998). Alkol ve Madde Kullanım Bozuklukları El Kitabı. Bakırköy Mental and Neurological Diseases Hospital, Amatem, Istanbul.

Uzbay, İ. T. (2009). Madde Bağımlılığının Tarihçesi, Tanımı, Genel Bilgiler ve Bağımlılık Ya- pan Maddeler, Türk Eczacılar Birliği Meslek İçi Sürekli Eğitim Dergisi, 21(22), 16-33.

Hay, S. I., Abajoir, A. A., Abate, K. H., Abbafati, C., Abbas, K.M., Abd-Allah, F. & GBD 2016 DALYs and HALE Collaborators. (2017). Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1260-1344.

Fox, K. A., Dabbous, O. H., Goldberg, R. J., Pieper, K. S., Eagle, K. A., Van de Werf, F., Ave- zum, A., Goodman, S. G., Flather, M. D., Anderson, F. A., Jr, & Granger, C. B. (2006). Predic- tion of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ (Clinical research ed.), 333(7578), 1091. https://doi.org/10.1136/bmj.38985.646481.55

Stevens, J., Erber, E., Truesdale, K. P., Wang, C. H., & Cai, J. (2013). Long- and short-term weight change and incident coronary heart disease and ischemic stroke: the Atherosclerosis Risk in Communities Study. American journal of epidemiology, 178(2), 239–248. https://doi. org/10.1093/aje/kws461

Mallaina, P., Lionis, C., Rol, H., Imperiali, R., Burgess, A., Nixon, M., & Malvestiti, F. M. (2013). Smoking cessation and the risk of cardiovascular disease outcomes predicted from established risk scores: results of the Cardiovascular Risk Assessment among Smokers in Primary Care in Europe (CV-ASPIRE) study. BMC public health, 13, 362. https://doi. org/10.1186/1471-2458-13-362

Sarımehmetoğlu, A. C., & Helvacı, A. (2014). Madde Bağımlılığı ve Kardiyovasküler Sistem.

Okmeydanı Tıp Dergisi, 30(2), 99-103. https://doi.org/10.5222/otd.supp2.2014.099

Nishimura, M., Bhatia, H., Ma, J., Dickson, S. D., Alshawabkeh, L., Adler, E., Maisel, A., Criqui, M. H., Greenberg, B., & Thomas, I. C. (2020). The Impact of Substance Abuse on Heart Failure Hospitalizations. The American journal of medicine, 133(2), 207–213.e1. https:// doi.org/10.1016/j.amjmed.2019.07.017

Nawrot, T. S., Perez, L., Künzli, N., Munters, E., & Nemery, B. (2011). Public health impor- tance of triggers of myocardial infarction: a comparative risk assessment. Lancet (London, England), 377(9767), 732–740. https://doi.org/10.1016/S0140-6736(10)62296-9

Atakan Z. (2012). Cannabis, a complex plant: different compounds and different effects on individuals. Therapeutic advances in psychopharmacology, 2(6), 241–254. https://doi. org/10.1177/2045125312457586

Singh, A., Saluja, S., Kumar, A., Agrawal, S., Thind, M., Nanda, S., & Shirani, J. (2018). Car- diovascular Complications of Marijuana and Related Substances: A Review. Cardiology and therapy, 7(1), 45–59. https://doi.org/10.1007/s40119-017-0102-x

DeFilippis, E. M., Bajaj, N. S., Singh, A., Malloy, R., Givertz, M. M., Blankstein, R., Bhatt, D. L., & Vaduganathan, M. (2020). Marijuana Use in Patients With Cardiovascular Disease: JACC Review Topic of the Week. Journal of the American College of Cardiology, 75(3), 320–332. https://doi.org/10.1016/j.jacc.2019.11.025

Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018). Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nature reviews. Cardiology, 15(3), 151–166. https://doi.org/10.1038/nrcardio.2017.130

Shayesteh, M. R. H., Haghi-Aminjan, H., Mousavi, M. J., Momtaz, S., & Abdollahi, M. (2019). The Protective Mechanism of Cannabidiol in Cardiac Injury: A Systematic Review of Non-C- linical Studies. Current pharmaceutical design, 25(22), 2499–2507. https://doi.org/10.2174/22 10327909666190710103103

Garza-Cervantes, J. A., Ramos-Gonzalez, M., Lozano, O., Jerjes-Sanchez, C., & Garcia-Rivas,

G. (2020). Therapeutic applications of cannabinoids in cardiomyopathy and heart failure. Oxi- dative Medicine and Cellular Longevity, 2020, 4587024. https://doi.org/10.1155/2020/4587024

Benowitz, N. L., Rosenberg, J., Rogers, W., Bachman, J., & Jones, R. T. (1979). Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clini- cal pharmacology and therapeutics, 25(4), 440–446. https://doi.org/10.1002/cpt1979254440

Gunawardena, M. D., Rajapakse, S., Herath, J., & Amarasena, N. (2014). Myocardial infarcti- on following cannabis induced coronary vasospasm. BMJ case reports, 2014, bcr2014207020. https://doi.org/10.1136/bcr-2014-207020

Casier, I., Vanduynhoven, P., Haine, S., Vrints, C., & Jorens, P. G. (2014). Is recent cannabis use associated with acute coronary syndromes? An illustrative case series. Acta cardiologica, 69(2), 131–136. https://doi.org/10.1080/ac.69.2.3017293

Frost, L., Mostofsky, E., Rosenbloom, J. I., Mukamal, K. J., & Mittleman, M. A. (2013). Mari- juana use and long-term mortality among survivors of acute myocardial infarction. American heart journal, 165(2), 170–175. https://doi.org/10.1016/j.ahj.2012.11.007

DeFilippis, E. M., Singh, A., Divakaran, S., Gupta, A., Collins, B. L., Biery, D., Qamar, A., Fatima, A., Ramsis, M., Pipilas, D., Rajabi, R., Eng, M., Hainer, J., Klein, J., Januzzi, J. L., Nasir, K., Di Carli, M. F., Bhatt, D. L., & Blankstein, R. (2018). Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction. Journal of the American College of Cardiology, 71(22), 2540-2551, https://doi.org/10.1016/j.jacc.2018.02.047

Kalla, A., Krishnamoorthy, P. M., Gopalakrishnan, A., & Figueredo, V. M. (2018). Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National In- patient Sample. Journal of cardiovascular medicine (Hagerstown, Md.), 19(9), 480–484. https:// doi.org/10.2459/JCM.0000000000000681

Nogi, M., Fergusson, D., & Chiaco, J. M. (2014). Mid-ventricular variant takotsubo cardiom- yopathy associated with Cannabinoid Hyperemesis Syndrome: a case report. Hawai’i jour- nal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 73(4), 115–118.

Singh, A., Fegley, M., Mana, Y., & Adrawal, S. (2016). Marijuana (cannabis) use is an indepen- dent predictor of stress cardiomyopathy in younger men. Circulation, 134(Suppl 1), A14100.

Kariyanna, P. T., Jayarangaiah, A., Singh, N., Song, T., Soroka, S., Amarnani, A., Ray, J. & McFarlane, S. I. (2018). Marijuana induced myocarditis: a new entity of toxic myocarditis. American Journal of Medical Case Reports, 6(9), 169-172.

Korantzopoulos P. (2014). Marijuana smoking is associated with atrial fibrillation. The Ame- rican journal of cardiology, 113(6), 1085–1086. https://doi.org/10.1016/j.amjcard.2014.01.001

Desai, R., Patel, U., Deshmukh, A., Sachdeva, R., & Kumar, G. (2018). Burden of arrhythmia in recreational marijuana users. International journal of cardiology, 264, 91–92. https://doi. org/10.1016/j.ijcard.2018.03.113

Baranchuk, A., Johri, A. M., Simpson, C. S., Methot, M., & Redfearn, D. P. (2008). Ventricular fibrillation triggered by marijuana use in a patient with ischemic cardiomyopathy: a case re- port. Cases journal, 1(1), 373. https://doi.org/10.1186/1757-1626-1-373

Yargıç, İ. (2013). Sentetik kannabinoidler. Proceedings of the Yeni Nesil Psiko-Aktif Maddeler Sempozyumu, Y. Küçük (Ed). Forensic Medicine Institute, Istanbul.

Pertwee R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & therapeutics, 74(2), 129–180. https://doi.org/10.1016/s0163-7258(97)82001-3

Winstock, A. R., & Barratt, M. J. (2013). Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and alcohol dependence, 131(1-2), 106–111. https://doi.org/10.1016/j.drugalcdep.2012.12.011

Liechti M. (2015). Novel psychoactive substances (designer drugs): overview and pharmaco- logy of modulators of monoamine signaling. Swiss medical weekly, 145, w14043. https://doi. org/10.4414/smw.2015.14043

Parlakpinar, H. , Celbis, O. , Ozhan, O. , Petekkaya, S. , Samdanci, E. , Ermis, N. , Koparir, P. , Soylu, O. & Acet, A. (2016). Cardiovascular effects of JWH-018 from synthetic cannabinoids. Medicine Science , 5 (4) , 1049-1054.

Fattore, L., & Fratta, W. (2011). Beyond THC: The New Generation of Cannabinoid Designer Drugs. Frontiers in behavioral neuroscience, 5, 60. https://doi.org/10.3389/fnbeh.2011.00060

TUBIM. (2013). Emniyet Genel Müdürlüğü Kaçakçılık ve Organize Suçlarla Mücadele Daire Başkanlığı EMCDDA 2013 Ulusal Raporu (2012 Yılı Verileri): Reitox Ulusal Temas Noktası Türkiye: Yeni Gelişmeler, Trendler, Seçilmiş Konular. Ankara, Türkiye Uyuşturucu ve Uyuştu- rucu Bağımlılığı İzleme Merkezi.

TUBIM. (2014). Emniyet Genel Müdürlüğü Kaçakçılık ve Organize Suçlarla Mücadele Daire Başkanlığı EMCDDA 2014 Ulusal Raporu (2013 Yılı Verileri) : Reitox Ulusal Temas Noktası Türkiye: Yeni Gelişmeler, Trendler, Seçilmiş Konular. Ankara, Türkiye Uyuşturucu ve Uyuştu- rucu Bağımlılığı İzleme Merkezi.

Cohen, J., Morrison, S., Greenberg, J., & Saidinejad, M. (2012). Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics, 129(4), e1064–e1067. https://doi. org/10.1542/peds.2011-1797

Brewer, T. L., & Collins, M. (2014). A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. Journal for specialists in pediatric nursing: JSPN, 19(2), 119–126. https://doi.org/10.1111/jspn.12057

Çınar, R., & Gündüz Çınar, Ö. (2012). Kannabinoid tip 1 reseptör (CB1) ve terapötik yakla- şımlara genel bakış-2. Marmara Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 1,149-154.

Gurdal, F., Asirdizer, M., Aker, R. G., Korkut, S., Gocer, Y., Kucukibrahimoglu, E. E., & Ince,

C. H. (2013). Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medici- ne, Turkey. Journal of forensic and legal medicine, 20(6), 667–672. https://doi.org/10.1016/j. jflm.2013.03.041

Schneir, A. B., Cullen, J., & Ly, B. T. (2011). “Spice” girls: synthetic cannabinoid intoxica- tion. The Journal of emergency medicine, 40(3), 296–299. https://doi.org/10.1016/j.jemer- med.2010.10.014

Vandrey, R., Dunn, K. E., Fry, J. A., & Girling, E. R. (2012). A survey study to characterize use of Spice products (synthetic cannabinoids). Drug and alcohol dependence, 120(1-3), 238–241. https://doi.org/10.1016/j.drugalcdep.2011.07.011

İbiloğlu A. O., Atlı A., & Güneş M. (2017). Sentetik Kannabinoidler. Psikiyatride Güncel Yak- laşımlar, 9(3), 317-328.

McKeever, R. G., Vearrier, D., Jacobs, D., LaSala, G., Okaneku, J., & Greenberg, M. I. (2015). K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 11(1), 129–131. https://doi.org/10.1007/s13181-014-0424-1

Hoyte, C. O., Jacob, J., Monte, A. A., Al-Jumaan, M., Bronstein, A. C., & Heard, K. J. (2012). A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Annals of emergency medicine, 60(4), 435–438. https://doi.org/10.1016/j.an- nemergmed.2012.03.007

Harris, C. R., & Brown, A. (2013). Synthetic cannabinoid intoxication: a case series and re- view. The Journal of emergency medicine, 44(2), 360–366. https://doi.org/10.1016/j.jemer- med.2012.07.061

Sasaki, C., Saito, T., Shinozuka, T. et al. A case of death caused by abuse of a synthetic cannabi- noid N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide. Forensic Toxicology, 33, 165–169 (2015). https://doi.org/10.1007/s11419-014-0246-5

Cornish, J. W., & O’Brien, C. P. (1996). Crack cocaine abuse: an epidemic with many public health consequences. Annual review of public health, 17, 259–273. https://doi.org/10.1146/ annurev.pu.17.050196.001355

Egred, M., & Davis, G. K. (2005). Cocaine and the heart. Postgraduate medical journal, 81(959), 568–571. https://doi.org/10.1136/pgmj.2004.028571

De Giorgi, A., Fabbian, F., Pala, M., Bonetti, F., Babini, I., Bagnaresi, I., Manfredini, F., Por- taluppi, F., Mikhailidis, D. P., & Manfredini, R. (2012). Cocaine and acute vascular diseases. Current drug abuse reviews, 5(2), 129–134. https://doi.org/10.2174/1874473711205020129

Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency De- partment Visits. U.S. Department of Health and Human Services Substance Abuse and Men- tal Health Services Administration Center for Behavioral Health Statistics and Quality. https:// www.samhsa.gov/data/sites/default/files/DAWN2k11ED/DAWN2k11ED/DAWN2k11ED. pdf

Kim, S. T., & Park, T. (2019). Acute and Chronic Effects of Cocaine on Cardiovascular Health.

International journal of molecular sciences, 20(3), 584. https://doi.org/10.3390/ijms20030584

Schwartz, B. G., Rezkalla S., & Kloner, R. A. (2010). Cardiovascular Effects of Cocaine. Circu- lation, 122, 2558–2569.

Davies, O., Ajayeoba, O., & Kurian, D. (2014). Coronary artery spasm: An often overloo- ked diagnosis. Nigerian medical journal: journal of the Nigeria Medical Association, 55(4), 356–358. https://doi.org/10.4103/0300-1652.137231

Talarico, G. P., Crosta, M. L., Giannico, M. B., Summaria, F., Calò, L., & Patrizi, R. (2017). Cocaine and coronary artery diseases: a systematic review of the literature. Journal of cardiovascular medicine (Hagerstown, Md.), 18(5), 291–294. https://doi.org/10.2459/ JCM.0000000000000511

Wilbert-Lampen, U., Seliger, C., Zilker, T., & Arendt, R.M. (1998). Cocaine increases the en- dothelial release of immunoreactive endothelin and its concentrations in human plasma and urine: Reversal by coincubation with sigma-receptor antagonists. Circulation, 98, 385–390.

Togna, G. I., Graziani, M., Russo, P., & Caprino, L. (2001). Cocaine toxic effect on endothe- lium-dependent vasorelaxation: an in vitro study on rabbit aorta. Toxicology letters, 123(1), 43–50. https://doi.org/10.1016/s0378-4274(01)00379-4

Mo, W., Singh, A. K., Arruda, J. A., & Dunea, G. (1998). Role of nitric oxide in cocaine-in- duced acute hypertension. American journal of hypertension, 11(6 Pt 1), 708–714. https://doi. org/10.1016/s0895-7061(98)00041-7

Perreault, C. L., Morgan, K. G., & Morgan, J. P. (1991). Effects of cocaine on intracellular calcium handling in cardiac and vascular smooth muscle. NIDA research monograph, 108, 139–153.

Scholz A. (2002). Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. British journal of anaesthesia, 89(1), 52–61. https://doi.org/10.1093/bja/aef163

Siegel, A. J., Sholar, M. B., Mendelson, J. H., Lukas, S. E., Kaufman, M. J., Renshaw, P. F., Mc- Donald, J. C., Lewandrowski, K. B., Apple, F. S., Stec, J. J., Lipinska, I., Tofler, G. H., & Ridker,

P. M. (1999). Cocaine-induced erythrocytosis and increase in von Willebrand factor: eviden- ce for drug-related blood doping and prothrombotic effects. Archives of internal medicine, 159(16), 1925–1929. https://doi.org/10.1001/archinte.159.16.1925

Goldstein, R. A., DesLauriers, C., Burda, A., & Johnson-Arbor, K. (2009). Cocaine: history, social implications, and toxicity: a review. Seminars in diagnostic pathology, 26(1), 10–17. htt- ps://doi.org/10.1053/j.semdp.2008.12.001

O’Leary M. E. (2002). Inhibition of HERG potassium channels by cocaethylene: a metabolite of cocaine and ethanol. Cardiovascular research, 53(1), 59–67. https://doi.org/10.1016/s0008- 6363(01)00458-8

Ferreira, S., Crumb, W. J., Jr, Carlton, C. G., & Clarkson, C. W. (2001). Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. The Journal of pharmacology and experimental therapeutics, 299(1), 220–226.

O’Leary, M. E., & Hancox, J. C. (2010). Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias. British journal of cli- nical pharmacology, 69(5), 427–442. https://doi.org/10.1111/j.1365-2125.2010.03629.x

Crandall, C. G., Vongpatanasin, W., & Victor, R. G. (2002). Mechanism of cocaine-indu- ced hyperthermia in humans. Annals of internal medicine, 136(11), 785–791. https://doi. org/10.7326/0003-4819-136-11-200206040-00006

Hoffman R. S. (2010). Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside. British journal of clinical pharmacology, 69(5), 448–457. https://doi.or- g/10.1111/j.1365-2125.2010.03632.x

Mouhaffel, A. H., Madu, E. C., Satmary, W. A., & Fraker, T. D., Jr (1995). Cardiovascular complications of cocaine. Chest, 107(5), 1426–1434. https://doi.org/10.1378/chest.107.5.1426

Sandoval, Y., Smith, S. W., Thordsen, S. E., & Apple, F. S. (2014). Supply/demand type 2 myo- cardial infarction: should we be paying more attention?. Journal of the American College of Cardiology, 63(20), 2079–2087. https://doi.org/10.1016/j.jacc.2014.02.541

Pradhan, L., Mondal, D., Chandra, S., Ali, M., & Agrawal, K. C. (2008). Molecular analysis of cocaine-induced endothelial dysfunction: role of endothelin-1 and nitric oxide. Cardiovascu- lar toxicology, 8(4), 161–171. https://doi.org/10.1007/s12012-008-9025-z

Bohm, F., & Pernow, J. (2007). The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovascular research, 76(1), 8–18. https://doi.org/10.1016/j.cardio- res.2007.06.004

Previtali, E., Bucciarelli, P., Passamonti, S. M., & Martinelli, I. (2011). Risk factors for venous and arterial thrombosis. Blood transfusion = Trasfusione del sangue, 9(2), 120–138. https:// doi.org/10.2450/2010.0066-10

Badimon, L., Padró, T., & Vilahur, G. (2012). Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. European heart journal. Acute cardiovascular care, 1(1), 60–74. https://doi.org/10.1177/2048872612441582

Wright, N. M., Martin, M., Goff, T., Morgan, J., Elworthy, R., & Ghoneim, S. (2007). Cocaine and thrombosis: a narrative systematic review of clinical and in-vivo studies. Substance abuse treatment, prevention, and policy, 2, 27. https://doi.org/10.1186/1747-597X-2-27

Graziani, M., Antonilli, L., Togna, A. R., Grassi, M. C., Badiani, A., & Saso, L. (2016). Car- diovascular and Hepatic Toxicity of Cocaine: Potential Beneficial Effects of Modulators of Oxidative Stress. Oxidative medicine and cellular longevity, 2016, 8408479. https://doi. org/10.1155/2016/8408479

Flores, E. D., Lange, R. A., Cigarroa, R. G., & Hillis, L. D. (1990). Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: enhanced vasoconstriction at sites of significant stenoses. Journal of the American College of Cardiology, 16(1), 74–79. https:// doi.org/10.1016/0735-1097(90)90459-3

Awtry, E. H., & Philippides, G. J. (2010). Alcoholic and cocaine-associated cardiomyopathies.

Progress in cardiovascular diseases, 52(4), 289–299. https://doi.org/10.1016/j.pcad.2009.11.004

Havakuk, O., Rezkalla, S. H., & Kloner, R. A. (2017). The Cardiovascular Effects of Cocai- ne. Journal of the American College of Cardiology, 70(1), 101–113. https://doi.org/10.1016/j. jacc.2017.05.014

Tazelaar, H. D., Karch, S. B., Stephens, B. G., & Billingham, M. E. (1987). Cocaine and the heart. Human pathology, 18(2), 195–199. https://doi.org/10.1016/s0046-8177(87)80338-6

Virmani, R., Robinowitz, M., Smialek, J. E., & Smyth, D. F. (1988). Cardiovascular effects of cocaine: an autopsy study of 40 patients. American heart journal, 115(5), 1068–1076. https:// doi.org/10.1016/0002-8703(88)90078-6

Isner, J. M., Estes, N. A., 3rd, Thompson, P. D., Costanzo-Nordin, M. R., Subramanian, R., Miller, G., Katsas, G., Sweeney, K., & Sturner, W. Q. (1986). Acute cardiac events temporally related to cocaine abuse. The New England journal of medicine, 315(23), 1438–1443. https:// doi.org/10.1056/NEJM198612043152302

Diercks, D. B., Fonarow, G. C., Kirk, J. D., Jois-Bilowich, P., Hollander, J. E., Weber, J. E., Wy- nne, J., Mills, R. M., Yancy, C., Peacock, W. F., 4th, & ADHERE Scientific Advisory Commit- tee and Investigators (2008). Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure Na- tional Registry Emergency Module). The American journal of cardiology, 102(9), 1216–1219. https://doi.org/10.1016/j.amjcard.2008.06.045

Dugo, E., Barison, A., Todiere, G., Grigoratos, C., & Aquaro, G. D. (2022). Cardiac magnetic resonance in cocaine-induced myocardial damage: cocaine, heart, and magnetic resonance. Heart failure reviews, 27(1), 111–118. https://doi.org/10.1007/s10741-020-09983-3

McCord, J., Jneid, H., Hollander, J. E., de Lemos, J. A., Cercek, B., Hsue, P., Gibler, W. B., Ohman, E. M., Drew, B., Philippides, G., Newby, L. K., & American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology (2008). Management of coca- ine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation, 117(14), 1897–1907. https://doi.org/10.1161/CIRCULATIONAHA.107.188950

Mann, B. K., Bhandohal, J. S., Saeed, M., & Pekler, G. (2020). Beta Blocker Therapy in Heart Failure Patients with Active Cocaine Use: A Systematic Review. Cardiology research and prac- tice, 2020, 1985379. https://doi.org/10.1155/2020/1985379

Maceira, A. M., Ripoll, C., Cosin-Sales, J., Igual, B., Gavilan, M., Salazar, J., Belloch, V., & Pen- nell, D. J. (2014). Long term effects of cocaine on the heart assessed by cardiovascular magne- tic resonance at 3T. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 16(1), 26. https://doi.org/10.1186/1532-429X-16-26

Hale, S. L., Alker, K. J., Rezkalla, S., Figures, G., & Kloner, R. A. (1989). Adverse effects of cocaine on cardiovascular dynamics, myocardial blood flow, and coronary artery diame- ter in an experimental model. American heart journal, 118(5 Pt 1), 927–933. https://doi. org/10.1016/0002-8703(89)90226-3

Pitts, W. R., Vongpatanasin, W., Cigarroa, J. E., Hillis, L. D., & Lange, R. A. (1998). Effects of the intracoronary infusion of cocaine on left ventricular systolic and diastolic function in humans. Circulation, 97(13), 1270–1273. https://doi.org/10.1161/01.cir.97.13.1270

Restrepo, C. S., Rojas, C. A., Martinez, S., Riascos, R., Marmol-Velez, A., Carrillo, J., & Vargas,

D. (2009). Cardiovascular complications of cocaine: imaging findings. Emergency radiology, 16(1), 11–19. https://doi.org/10.1007/s10140-008-0762-x

Felker, G. M., Hu, W., Hare, J. M., Hruban, R. H., Baughman, K. L., & Kasper, E. K. (1999).

The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients.

Medicine, 78(4), 270–283. https://doi.org/10.1097/00005792-199907000-00005

Patrizi, R., Pasceri, V., Sciahbasi, A., Summaria, F., Rosano, G. M., & Lioy, E. (2006). Eviden- ce of cocaine-related coronary atherosclerosis in young patients with myocardial infarction. Journal of the American College of Cardiology, 47(10), 2120–2122. https://doi.org/10.1016/j. jacc.2005.12.060

Steinhauer, J. R., & Caulfield, J. B. (2001). Spontaneous coronary artery dissection associated with cocaine use: a case report and brief review. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology, 10(3), 141–145. https://doi.org/10.1016/s1054- 8807(01)00074-6

Kamineni, R., Sadhu, A., & Alpert, J. S. (2002). Spontaneous coronary artery dissection: re- port of two cases and a 50-year review of the literature. Cardiology in review, 10(5), 279–284. https://doi.org/10.1097/00045415-200209000-00004

Meghani, M., Siddique, M. N., Bhat, T., Samarneh, M., & Elsayegh, S. (2013). Internal carotid artery redundancy and dissection in a young cocaine abuser. Vascular, 21(4), 243–245. htt- ps://doi.org/10.1177/1708538113478765

Huang, M., Pang, X., Letourneau, R., Boucher, W., & Theoharides, T. C. (2002). Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in Apoli- poprotein E knockout mice. Cardiovascular research, 55(1), 150–160. https://doi.org/10.1016/ s0008-6363(02)00336-x

Lindstedt, K. A., Mäyränpää, M. I., & Kovanen, P. T. (2007). Mast cells in vulnerable atherosc- lerotic plaques--a view to a kill. Journal of cellular and molecular medicine, 11(4), 739–758. https://doi.org/10.1111/j.1582-4934.2007.00052.x

Rangel, C., Shu, R. G., Lazar, L. D., Vittinghoff, E., Hsue, P. Y., & Marcus, G. M. (2010). Be- ta-blockers for chest pain associated with recent cocaine use. Archives of internal medicine, 170(10), 874–879. https://doi.org/10.1001/archinternmed.2010.115

Lopez, P. D., Akinlonu, A., Mene-Afejuku, T. O., Dumancas, C., Saeed, M., Cativo, E. H., Visco, F., Mushiyev, S., & Pekler, G. (2019). Clinical outcomes of Β-blocker therapy in co- caine-associated heart failure. International journal of cardiology, 277, 153–158. https://doi. org/10.1016/j.ijcard.2018.08.058

Dattilo, P. B., Hailpern, S. M., Fearon, K., Sohal, D., & Nordin, C. (2008). Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Annals of emergency medicine, 51(2), 117–125. https://doi.org/10.1016/j.annemergmed.2007.04.015

United Nations Office on Drugs and Crime, (2016), World Drug Report. Vienna: United Na- tion.

Döğer, R. (2016). Metamfetamin ve MDMA (EKSTAZİ)nın idrar ve saçta kromatografik yön- temlerle tayini. Unpublished Master thesis. The Graduate School of Health Sciences, Ege Uni- versity, Izmir, Turkey.

Hoffman RJ. (2008). MDMA (ecstasy) intoxication. http://www.uptodate.com

Kevil, C. G., Goeders, N. E., Woolard, M. D., Bhuiyan, M. S., Dominic, P., Kolluru, G. K., Arnold, C. L., Traylor, J. G., & Orr, A. W. (2019). Methamphetamine Use and Cardiovascu- lar Disease. Arteriosclerosis, thrombosis, and vascular biology, 39(9), 1739–1746. https://doi. org/10.1161/ATVBAHA.119.312461

Mendelson, J., Uemura, N., Harris, D., Nath, R. P., Fernandez, E., Jacob, P., 3rd, Everhart, E. T., & Jones, R. T. (2006). Human pharmacology of the methamphetamine stereoisomers. Clinical pharmacology and therapeutics, 80(4), 403–420. https://doi.org/10.1016/j.clpt.2006.06.013

Lord, K. C., Shenouda, S. K., McIlwain, E., Charalampidis, D., Lucchesi, P. A., & Varner, K. J. (2010). Oxidative stress contributes to methamphetamine-induced left ventricular dysfuncti- on. Cardiovascular research, 87(1), 111–118. https://doi.org/10.1093/cvr/cvq043

Varner, K. J., Hein, N. D., Ogden, B. A., Arsenault, J. R., Carter, K. M., & Soine, W. H. (2001). Chloroephedrine: contaminant of methamphetamine synthesis with cardiovascular activity. Drug and alcohol dependence, 64(3), 299–307. https://doi.org/10.1016/s0376-8716(01)00132- 6

Darke, S., Kaye, S., McKetin, R., & Duflou, J. (2008). Major physical and psychologi- cal harms of methamphetamine use. Drug and alcohol review, 27(3), 253–262. https://doi. org/10.1080/09595230801923702

Chin, K. M., Channick, R. N., & Rubin, L. J. (2006). Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. Chest, 130(6), 1657–1663. https://doi. org/10.1378/chest.130.6.1657

Swalwell, C. I., & Davis, G. G. (1999). Methamphetamine as a risk factor for acute aortic dis- section. Journal of forensic sciences, 44(1), 23–26.

Satendra, M., de Jesus, C., Bordalo e Sá, A. L., Rosário, L., Rocha, J., Bicha Castelo, H., Cor- reia, M. J., & Nunes Diogo, A. (2014). Reversible catecholamine-induced cardiomyopathy due to pheochromocytoma: case report. Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 33(3), 177.e1–177.e1776. https://doi.org/10.1016/j. repc.2013.09.011

Ferreira, V. M., Marcelino, M., Piechnik, S. K., Marini, C., Karamitsos, T. D., Ntusi, N. A. B., Francis, J. M., Robson, M. D., Arnold, J. R., Mihai, R., Thomas, J. D. J., Herincs, M., Has- san-Smith, Z. K., Greiser, A., Arlt, W., Korbonits, M., Karavitaki, N., Grossman, A. B., Wass,

J. A. H., & Neubauer, S. (2016). Pheochromocytoma Is Characterized by Catecholamine-Me- diated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. Journal of the American College of Cardiology, 67(20), 2364–2374. https://doi.org/10.1016/j. jacc.2016.03.543

Islam, M. N., Jesmine, K., Kong Sn Molh, A., & Hasnan, J. (2009). Histopathological stu- dies of cardiac lesions after long term administration of methamphetamine in high dosa- ge--Part II. Legal medicine (Tokyo, Japan), 11 Suppl 1, S147–S150. https://doi.org/10.1016/j. legalmed.2009.02.035

Yi, S. H., Ren, L., Yang, T. T., Liu, L., Wang, H., & Liu, Q. (2008). Myocardial lesions after long- term administration of methamphetamine in rats. Chinese medical sciences journal = Chung- kuo i hsueh k’o hsueh tsa chih, 23(4), 239–243. https://doi.org/10.1016/s1001-9294(09)60046-8

Yeo, K. K., Wijetunga, M., Ito, H., Efird, J. T., Tay, K., Seto, T. B., Alimineti, K., Kimata, C., & Schatz, I. J. (2007). The association of methamphetamine use and cardiomyopathy in young patients. The American journal of medicine, 120(2), 165–171. https://doi.org/10.1016/j.amj- med.2006.01.024

Kumai, T., Inamasu, J., Watanabe, E., Sugimoto, K., & Hirose, Y. (2016). Differences between Takotsubo cardiomyopathy and reverse Takotsubo cardiomyopathy associated with subara- chnoid hemorrhage. International journal of cardiology. Heart & vasculature, 11, 99–103. htt- ps://doi.org/10.1016/j.ijcha.2016.05.010

Chehab, O., Ioannou, A., Sawhney, A., Rice, A., & Dubrey, S. (2017). Reverse Takotsubo Cardiomyopathy and Cardiogenic Shock Associated With Methamphetamine Consump- tion. The Journal of emergency medicine, 53(5), e81–e83. https://doi.org/10.1016/j.jemer- med.2017.06.027

Haning, W., & Goebert, D. (2007). Electrocardiographic abnormalities in methamphetamine abusers. Addiction (Abingdon, England), 102 Suppl 1, 70–75. https://doi.org/10.1111/j.1360- 0443.2006.01776.x

Huang, M. C., Yang, S. Y., Lin, S. K., Chen, K. Y., Chen, Y. Y., Kuo, C. J., & Hung, Y. N. (2016). Risk of Cardiovascular Diseases and Stroke Events in Methamphetamine Users: A 10-Year Follow-Up Study. The Journal of clinical psychiatry, 77(10), 1396–1403. https://doi. org/10.4088/JCP.15m09872

Zheng, X. Z., Shi, Y. Y., Chen, K. Q., Qiao, X. L., & Wang, L. Y. (2019). Evaluation of regio- nal myocardial perfusion in methamphetamine abusers using real-time myocardial contrast echocardiography. Medical ultrasonography, 21(1), 56–61. https://doi.org/10.11152/mu-1679

Schürer, S., Klingel, K., Sandri, M., Majunke, N., Besler, C., Kandolf, R., Lurz, P., Luck, M., Hertel, P., Schuler, G., Linke, A., & Mangner, N. (2017). Clinical Characteristics, Histopatho- logical Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. JACC. Heart failure, 5(6), 435–445. https://doi.org/10.1016/j.jchf.2017.02.017

Janardhanan, R., & Kannan, A. (2016). Methamphetamine cardiotoxicity: unique presentati- on with multiple biventricular thrombi. The American Journal of Medicine, 129(1), e3–e4.

Kollins, S. H., MacDonald, E. K., & Rush, C. R. (2001). Assessing the abuse potential of met- hylphenidate in nonhuman and human subjects: a review. Pharmacology, biochemistry, and behavior, 68(3), 611–627. https://doi.org/10.1016/s0091-3057(01)00464-6

Volkow, N. D., Fowler, J. S., Gatley, S. J., Dewey, S. L., Wang, G. J., Logan, J., Ding, Y. S., Fran- ceschi, D., Gifford, A., Morgan, A., Pappas, N., & King, P. (1999). Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse (New York, N.Y.), 31(1), 59–66. https://doi.org/10.1002/(SICI)1098-2396(199901)31:1<59::AI D-SYN8>3.0.CO;2-Y

Türkmenoğlu, Y. E., Esedova, C., Akpinar, M., Uysal, T., & İrdem, A. (2020). Effects of me- dications on ventricular repolarization in children with attention deficit hyperactivity di- sorder. International clinical psychopharmacology, 35(2), 109–112. https://doi.org/10.1097/ YIC.0000000000000288

Shin, J. Y., Roughead, E. E., Park, B. J., & Pratt, N. L. (2016). Cardiovascular safety of methy- lphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ (Clinical research ed.), 353, i2550. https://doi.org/10.1136/bmj.i2550

Fay, T. B., & Alpert, M. A. (2019). Cardiovascular Effects of Drugs Used to Treat Attention-De- ficit/Hyperactivity Disorder Part 2: Impact on Cardiovascular Events and Recommendations for Evaluation and Monitoring. Cardiology in review, 27(4), 173–178. https://doi.org/10.1097/ CRD.0000000000000234

Masoudkabir, F., Sarrafzadegan, N. & Eisenberg, M. (2013). Effects of opium consumption on cardiometabolic diseases. Nature Reviews Cardiology, 10, 733–740. https://doi.org/10.1038/ nrcardio.2013.159

Schiff Jr, P. L. (2002). Opium and its alkaloids. American Journal of Pharmaceutical Educati- on, 66, 186-194.

Traynor J. (2012). μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology. Drug and alcohol dependen- ce, 121(3), 173–180. https://doi.org/10.1016/j.drugalcdep.2011.10.027

Kalant H. (1997). Opium revisited: a brief review of its nature, composition, non-medical use and relative risks. Addiction (Abingdon, England), 92(3), 267–277.

Asgary, S., Sarrafzadegan, N., Naderi, G. A., & Rozbehani, R. (2008). Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of admi- nistration matter? Lipids in health and disease, 7, 42. https://doi.org/10.1186/1476-511X-7-42

UNODC. (2019). World Drug Report.

Amin-Esmaeili, M., Rahimi-Movaghar, A., Sharifi, V., Hajebi, A., Radgoodarzi, R., Mojtabai, R., Hefazi, M., & Motevalian, A. (2016). Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addiction (Abingdon, England), 111(10), 1836–1847. https://doi.org/10.1111/ add.13453

Farahani, M. A., Ghaffari, F., & Seyed Fatemi, N. (2015). Opium addiction in patients with coronary artery disease: a grounded theory study. Medical journal of the Islamic Republic of Iran, 29, 267.

Mohammadi, A., Darabi, M., Nasry, M., Saabet-Jahromi, M. J., Malek-Pour-Afshar, R., & Sheibani, H. (2009). Effect of opium addiction on lipid profile and atherosclerosis formati- on in hypercholesterolemic rabbits. Experimental and toxicologic pathology: official journal of the Gesellschaft fur Toxikologische Pathologie, 61(2), 145–149. https://doi.org/10.1016/j. etp.2008.08.001

Singleton, J. H., Abner, E. L., Akpunonu, P. D., & Kucharska-Newton, A. M. (2021). Associ- ation of Nonacute Opioid Use and Cardiovascular Diseases: A Scoping Review of the Lite- rature. Journal of the American Heart Association, 10(13), e021260. https://doi.org/10.1161/ JAHA.121.021260

Schultz, J. E., & Gross, G. J. (2001). Opioids and cardioprotection. Pharmacology & therapeu- tics, 89(2), 123–137. https://doi.org/10.1016/s0163-7258(00)00106-6

Nakhaee, S., Amirabadizadeh, A., Qorbani, M., Lamarine, R. J., & Mehrpour, O. (2020). Opi- um use and cardiovascular diseases: a systematic review and meta-analysis. Critical reviews in toxicology, 50(3), 201–212. https://doi.org/10.1080/10408444.2020.1740972

Osterwalder J. J. (1995). Patients intoxicated with heroin or heroin mixtures: how long should they be monitored?. European journal of emergency medicine: official journal of the European Society for Emergency Medicine, 2(2), 97–101. https://doi.org/10.1097/00063110-199506000- 00009

Ghuran, A., & Nolan, J. (2000). Recreational drug misuse: issues for the cardiologist. Heart (British Cardiac Society), 83(6), 627–633. https://doi.org/10.1136/heart.83.6.627

Aghadavoudi, O., Eizadi-Mood, N., & Najarzadegan, M. R. (2015). Comparing cardiovascu- lar factors in opium abusers and non-users candidate for coronary artery bypass graft surgery. Advanced biomedical research, 4, 12. https://doi.org/10.4103/2277-9175.148294

Zagaria, M. A. E. (2018). Cardiovascular considerations with prescription opioids and chro- nic pain. US Pharm, 43, 6–9.

Nakhaee, S., Ghasemi, S., Karimzadeh, K., Zamani, N., Alinejad-Mofrad, S., & Mehrpour, O. (2020). The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms. Substance abuse treatment, prevention, and policy, 15(1), 30. https:// doi.org/10.1186/s13011-020-00272-8

Esmaeili Nadimi, A., Pour Amiri, F., Sheikh Fathollahi, M., Hassanshahi, G., Ahmadi, Z., & Sayadi, A. R. (2016). Opium addiction as an independent risk factor for coronary microvas- cular dysfunction: A case-control study of 250 consecutive patients with slow-flow angina. International journal of cardiology, 219, 301–307. https://doi.org/10.1016/j.ijcard.2016.06.034

Masoumi, M. (2019). Opium Is an Important Risk Factor for Coronary Artery Ectasia; a Cross-Sectional Study. Preprint (Version 1), https://doi.org/10.21203/rs.2.16809/v1

Roayaei, P., Aminorroaya, A., Vasheghani-Farahani, A., Oraii, A., Sadeghian, S., Poorhosseini, H., & Masoudkabir, F. (2020). Opium and cardiovascular health: A devil or an angel?. Indian heart journal, 72(6), 482–490. https://doi.org/10.1016/j.ihj.2020.10.003

Sakai, J.T., & Crowley, T.J. (2009) Inhalant-related disorders. In B. J. Sadock, V. A. Sadock, &

P. Ruiz (Eds.) Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, 9th edition, pp. 1341- 1353. Lippincott Williams Wilkins, Baltimore.

Williams, J. F., Storck, M., American Academy of Pediatrics Committee on Substance Abuse, & American Academy of Pediatrics Committee on Native American Child Health (2007). Inhalant abuse. Pediatrics, 119(5), 1009–1017. https://doi.org/10.1542/peds.2007-0470

Flanagan, R. J., Ruprah, M., Meredith, T. J., & Ramsey, J. D. (1990). An introduction to the clinical toxicology of volatile substances. Drug safety, 5(5), 359–383. https://doi. org/10.2165/00002018-199005050-00005

Ives R. (2000). Disorders relating to the use of volatile substance. In M. G. Gelder, J. J. Lopez Ibor, & N. C. Andreasen (Eds.) New Oxford Textbook of Psychiatry. Oxford University Press, New York.

Kumar, S., Grover, S., Kulhara, P., Mattoo, S. K., Basu, D., Biswas, P., & Shah, R. (2008). In- halant abuse: A clinic-based study. Indian journal of psychiatry, 50(2), 117–120. https://doi. org/10.4103/0019-5545.42399

Ridenour T. A. (2005). Inhalants: not to be taken lightly anymore. Current opinion in psychi- atry, 18(3), 243–247. https://doi.org/10.1097/01.yco.0000165593.52811.cd

Yücel, M., Takagi, M., Walterfang, M., & Lubman, D. I. (2008). Toluene misuse and long- term harms: a systematic review of the neuropsychological and neuroimaging literature. Neuroscience and biobehavioral reviews, 32(5), 910–926. https://doi.org/10.1016/j.neubio- rev.2008.01.006

Yücel, M., Lubman, D. I., Solowij, N., & Brewer, W. J. (2007). Understanding drug addicti- on: a neuropsychological perspective. The Australian and New Zealand journal of psychiatry, 41(12), 957–968. https://doi.org/10.1080/00048670701689444

Vural, M., & Öğel, K. (2005). Uçucu maddelerin kalp üzerine etkileri. Journal of Dependen- ce, 6(3), 142-146.

Flanagan, R. J., & Ives, R. J. (1994). Volatile substance abuse. Bulletin on narcotics, 46(2), 49– 78.

Ridenour, T. A., Bray, B. C., & Cottler, L. B. (2007). Reliability of use, abuse, and dependen- ce of four types of inhalants in adolescents and young adults. Drug and alcohol dependence, 91(1), 40–49. https://doi.org/10.1016/j.drugalcdep.2007.05.004

Wu, L. T., & Ringwalt, C. L. (2006). Inhalant use and disorders among adults in the Uni- ted States. Drug and alcohol dependence, 85(1), 1–11. https://doi.org/10.1016/j.drugalc- dep.2006.01.017

Medina-Mora, M. E., & Real, T. (2008). Epidemiology of inhalant use. Current opinion in psychiatry, 21(3), 247–251. https://doi.org/10.1097/YCO.0b013e3282fc9875

Wick, R., Gilbert, J. D., Felgate, P., & Byard, R. W. (2007). Inhalant deaths in South Australia: a 20-year retrospective autopsy study. The American journal of forensic medicine and pathology, 28(4), 319–322. https://doi.org/10.1097/PAF.0b013e31815b48b0

Wiseman, M. N., & Banim, S. (1987). “Glue sniffer’s” heart? British medical journal (Clinical research ed.), 294(6574), 739. https://doi.org/10.1136/bmj.294.6574.739

Borowiak, K. S., Ciechanowski, K., & Waloszczyk, P. (1998). Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. Journal of toxicology. Clinical toxico- logy, 36(1-2), 47–49. https://doi.org/10.3109/15563659809162584